Skip to content

Study · Animal study (in vivo) · rat · 1991

3 results

Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation.

Pizcueta MP, García-Pagán JC, Fernández M, Casamitjana R, Bosch J, Rodés J

Gastroenterology1 Dec 1991Cited by 57 (Europe PMC)

PMID1683327 (opens in a new tab)DOI10.1016/0016-5085(91)90411-d (opens in a new tab)PepBankPUB-01683327
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In portal hypertensive rats, adding glucagon abolished all reported hemodynamic effects of somatostatin.

    In plain wordsIn rats with portal hypertension, added glucagon abolished somatostatin's blood-flow and pressure effects compared with somatostatin alone.

    Peptide
    Glucagon
    Outcome
    MixedSomatostatin hemodynamic effects
    Study

    ratn: not reported in source

    Partial portal vein ligation-induced portal hypertension
    Comparator
    Somatostatin alone
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.8 ng/min · infusionAs given in this study (rat).

    Source sentences

    Summary
    The simultaneous infusion of somatostatin and glucagon (2.8 ng/min, a dose that prevented any decrease in circulating glucagon levels) abolished all the hemodynamic effects of somatostatin.
    2 context sentences
    Summary · context
    Somatostatin infusion significantly decreased portal pressure (from 13.1 +/- 1.9 to 12.1 +/- 2.2 mm Hg; P less than 0.05). This was associated with a significant decrease in portal venous inflow caused by splanchnic vasoconstriction, as evidenced by increased splanchnic vascular resistance, and with…
    Summary · context
    Splanchnic vascular resistance and splanchnic blood flow were determined using radioactive microspheres in rats with portal hypertension caused by partial portal vein ligation.
  2. 02AnimalAnimal study (in vivo)Pharmacokinetics

    In portal hypertensive rats, added glucagon prevented any decrease in circulating glucagon during somatostatin infusion.

    In plain wordsIn rats with portal hypertension, added glucagon prevented the fall in glucagon during somatostatin infusion.

    Peptide
    Glucagon
    Outcome
    IncreaseCirculating glucagon preservation
    Study

    ratn: not reported in source

    Partial portal vein ligation-induced portal hypertension
    Comparator
    Somatostatin alone
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    2.8 ng/min · infusionAs given in this study (rat).

    Source sentences

    Summary
    The simultaneous infusion of somatostatin and glucagon (2.8 ng/min, a dose that prevented any decrease in circulating glucagon levels) abolished all the hemodynamic effects of somatostatin.
    1 context sentence
    Summary · context
    Splanchnic vascular resistance and splanchnic blood flow were determined using radioactive microspheres in rats with portal hypertension caused by partial portal vein ligation.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In portal hypertensive rats receiving glucagon alone, no hemodynamic changes were reported.

    In plain wordsIn rats with portal hypertension, glucagon alone produced no reported changes in blood-flow measures.

    Peptide
    Glucagon
    Outcome
    Direction not reportedHemodynamic changes with glucagon alone
    Study

    ratn: not reported in source

    Partial portal vein ligation-induced portal hypertension
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.8 ng/min · infusionAs given in this study (rat).

    Source sentences

    Summary
    This effect seems to be specific because no hemodynamic changes were noted in portal hypertensive rats receiving only the glucagon infusion.
    1 context sentence
    Summary · context
    Splanchnic vascular resistance and splanchnic blood flow were determined using radioactive microspheres in rats with portal hypertension caused by partial portal vein ligation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.